CAMBRIDGE, Mass., Oct. 16 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) today announced it has signed an agreement with Microbix Biosystems Inc. of Toronto, Canada for the manufacturing of high quality adenoviral stocks to be tested in the mouse mode of Amyotrophic Lateral Sclerosis (ALS).